BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
Introduction
• Page 5, line 19: you state that "a substantial proportion of patients with IHDs does not receive guideline recommended care". This should be quantified (e.g. what %) to demonstrate the scale of the problem • The review focused on interventions to change clinicians behaviour; however, prescribing is a complex behaviour and there are many different barriers to prescribing including patient factors, organisational/ resource constraints and healthcare professional factors. Therefore, there needs to be a stronger rationale for why the review only looked at interventions for healthcare professionals and not any intervention to improve prescribing. Furthermore, these other barriers need to be acknowledged and discussed.
• Page 5, lines 52-56: need to make explicit that the review is focused on interventions targeted at health care professionals Methods • The methods section is clear and comprehensively described • What is the rationale for not including non-randomised controlled trials or cohort studies?
Results
• It is concerning that 452 additional records were identified from reference lists and not picked up in the electronic database searches. This suggests that the search strategy was not adequate. How confident can you be that you have included all relevant studies give this and the fact that you only searched 2 electronic databases, only included English language papers and didn't look at grey literature? This is particularly important because you conclude that more studies are required from low/middle income countries, but could this lack of studies be a result of your search strategy and exclusion of non-English language papers rather than a lack of studies?
• Figure 1 : What do you mean by qualitative and quantitative synthesis? The methods include not mention of qualitative data.
• Figure 2 : I suspect that this figure will be too small for a large proportion of people to read and interpret • I believe it would be more useful to combine studies by intervention type rather that drugs prescribed. It is more useful for health care professionals to know what type of intervention is the most effective at improving prescribing of any primary prevention drug rather than whether any intervention improves prescribing.
• What is the logic for looking at change in BP, cholesterol and mortality. If the logic is that improving prescribing will improve these outcomes then why include studies in this analysis that did not improve prescribing rates?
• I question the statement that there is no substantial heterogeneity. Although the I2 are below 50% the studies are very heterogeneous in terms of intervention type, location, setting, diagnosis etc. For example, from eyeballing Figure 2.D you can clearly see that there is heterogeneity despite the I2 = 0% Discussion • Clustering all intervention types together does not provide useful information for the readers of this paper. It would be more useful to know which interventions are most effective rather than combining different types. Furthermore, although the meta analysis found a significant effect for lipid lowering drug prescribing, the evidence from individual studies is less convincing (only 1 out of 12 studies was significant). I would like to see more subjective discussion around the results rather than reliance on the meta analysis.
• Discussion should be added regarding combining heterogeneous studies in a meta analysis regardless of I2 values • The lack of low/middle income countries could be a result of your search strategy and exclusion of non-English language papers rather than a lack of studies, this should be acknowledged • I disagree with the statement on page 11, lines 23-28: "Most likely the high baseline performance, especially of antiplatelet agents, limited the scope for further improvement". Prescribing behaviour is complex and involves a multitude of different barriers. Therefore you can't conclude why the interventions did not work without a full process evaluation. These other barriers, e.g. patient factors/ organisational constraints, need to be addressed. Furthermore, baseline prescribing should be presented in the results.
REVIEWER

Robert M West University of Leeds UK
REVIEW RETURNED
19-Jul-2017
GENERAL COMMENTS
The research question is of interest and is to some extent answered by the SR provided. The editor may wish to review the priority for publication since there have been two related reviews publishedthese are discussed within this manuscript.
It is clear that the major limitation of this SR is that the interventions identified in publications are heterogeneous. The material in the appendix giving details of sub-analyses attempts to separate the different effects from different types of intervention. The conclusion is that the intervention increases statin prescription and improves blood pressure. Other outcomes all improve but not to a statistically significant level. It would be expected that an increase in statins would mean better BP and also better cholesterol, yet the improvement for cholesterol remains small and statistically nonsignificant. Some discussion of this might be useful.
REVIEWER
Xiaoju Zhang Abbott Laboratories, USA REVIEW RETURNED
15-Aug-2017
GENERAL COMMENTS
This meta-analysis study of interventions effects of ischemic heart diseases was rigorously designed. From 13 included studies, including four RCTs (1,869 patients) and nine cluster RCTs (15,224 patients), this study found that the interventions significantly enhanced prescribing of statins/lipid lowering agents, and significant association between the interventions and improved health outcomes for target blood pressure. The description of the methods for the literature selection is complete and clear. To keep the high quality of the literature selection, besides independent reviewers, the authors conducted extra layers of quality control tests to avoid publication bias. In addition, the authors did a very comprehensive discussion on the findings, including the alternative explanations and the limitations of the studies included in this analysis.
In all, this mata-analysis study holds good quality, and it could add significant values into clinic.
Minor Issues: -. Page2. "01st" should be "1st" -. Reviewer's comment 5: Introduction: The review focused on interventions to change clinicians behaviour; however, prescribing is a complex behaviour and there are many different barriers to prescribing including patient factors, organisational/ resource constraints and healthcare professional factors. Therefore, there needs to be a stronger rationale for why the review only looked at interventions for healthcare professionals and not any intervention to improve prescribing. Furthermore, these other barriers need to be acknowledged and discussed.
Author's response 5:
We agree with the reviewer that prescribing is a complex behaviour and there are many different barriers. We have amended the introduction to address this point as follows (page 5, lines 53-57 and page 6, lines 2-3): "In this review we focus on interventions targeted at health professionals. Other factors influencing prescribing, such as patient behavior, organizational factors or resource constraints are outside the scope of this review." Furthermore, we highlight the importance of considering all different kinds of barriers in the discussion section as follows (page 14, lines 38-50): "Selecting an intervention to enhance prescribing according to guidelines should be based on the local context. Interventions need to consider a range of barriers to change prescribing, including barriers related to patients, organization of the health care system and resource constraints. Finally, improving guideline adherence may include strategies for improving clinicians' awareness, agreement, and adoption of guidelines. The cost-effectiveness of such interventions should also be evaluated."
Reviewer's comment 6: Introduction: Page 5, lines 52-56: need to make explicit that the review is focused on interventions targeted at health care professionals Authors' response 6: We have changed the sentence as suggested.
Reviewer's comment 7: Methods • The methods section is clear and comprehensively described • What is the rationale for not including non-randomised controlled trials or cohort studies?
Authors' response 7: We only included randomized controlled trials because they are more likely to provide unbiased information than other study designs. In this, we follow the line of arguments in The Cochrane Handbook for Systematic Reviews of Interventions suggesting that reviews of non-randomised controlled trials or cohort studies should only be undertaken when the question of interest cannot be answered by a review of randomized controlled trials.
Reviewer's comment 8: Results: It is concerning that 452 additional records were identified from reference lists and not picked up in the electronic database searches. This suggests that the search strategy was not adequate. How confident can you be that you have included all relevant studies give this and the fact that you only searched 2 electronic databases, only included English language papers and didn't look at grey literature? This is particularly important because you conclude that more studies are required from low/middle income countries, but could this lack of studies be a result of your search strategy and exclusion of non-English language papers rather than a lack of studies?
Authors' response 8: This seems to be a misunderstanding. We have reviewed the reference lists of the 13 included studies (in total 452 references) to identify potentially relevant articles we may have missed by Pubmed/EMBASE. However, no additional relevant studies were identified from those references. In our view, PUBMED and EMBASE cover the relevant literature of controlled trials in this subject area. But we have amended the discussion section to be more explicit about the limitations of our study as follows (page 14, lines 20-26): "Finally, our review included only studies published in English and we did not search for gray literature. So we may have missed relevant unpublished or locally published studies." Furthermore, as highlighted above, we have modified our conclusion and removed the part on the lack of studies in low-income and middle-income countries.
Reviewer's comment 9: Results:
• Figure Reviewer's comment 10: Results: I believe it would be more useful to combine studies by intervention type rather that drugs prescribed. It is more useful for health care professionals to know what type of intervention is the most effective at improving prescribing of any primary prevention drug rather than whether any intervention improves prescribing.
Authors' response 10: We did do subgroup analyses based on intervention type (professional vs organizational vs mixed interventions, based on the EPOC classification) but there were no significant differences. Furthermore, we acknowledged this issue in the discussion section as follows (page 13, lines 51-57 and page 14, lines 2-10): "Third, we included studies of all types of interventions targeted at health care professionals in the meta-analyses. Subgroup analyses showed that there was no significant difference between subgroups of interventions (professional, organizational, and professional plus organizational).
But more detailed analyses, e.g. on duration or intensity of the intervention, were impossible due to the limited number of studies. The length of patient follow-up varied across studies. This issue might increase the clinical heterogeneity of outcomes measured." Moreover, most of the included studies reported results of individual medications rather than providing results of combined use. Furthermore, we believe it is useful to analyse results separately for the different medications as there may be differences in adhering to the guidelines for the different medications.
Reviewer's comment 11: Results: What is the logic for looking at change in BP, cholesterol and mortality. If the logic is that improving prescribing will improve these outcomes then why include studies in this analysis that did not improve prescribing rates?
Authors' response 11:
We agree with the reviewer that this is an important point. We have addressed the question why we see changes in outcomes without changes in prescribing rates in the discussion section as follows (page 12, lines 29-48): "Whether or not adequate dosing had been achieved was not measured in the trials, but this has an effect on patients' outcomes. For example, the benefits of more intensive therapy with statins have been established. Lack of patient adherence with medication could also be an explanation, but this was not measured in the trials. Patient adherence is reported to be better with antihypertensive agents than with statins. In addition, lifestyle modifications also contribute to patients' clinical outcomes and may have played an important role in improving blood pressure control. More work is needed to disentangle the associations. In particular, because our analyses for blood pressure and LDL-C/cholesterol levels were based on a few studies only." Authors' response 12: We agree with your comments. We did clarify statistical or clinical heterogeneity in our manuscript.
Reviewer's comment 13: Discussion: Clustering all intervention types together does not provide useful information for the readers of this paper. It would be more useful to know which interventions are most effective rather than combining different types. Furthermore, although the meta analysis found a significant effect for lipid lowering drug prescribing, the evidence from individual studies is less convincing (only 1 out of 12 studies was significant). I would like to see more subjective discussion around the results rather than reliance on the meta analysis.
Author's response 13: As highlighted above, we did do subgroup analyses based on intervention type (professional vs organizational vs mixed interventions, based on the EPOC classification) but there were no significant differences. Furthermore, we acknowledged this issue in the discussion section as follows (page 13, lines 51-57 and page 14, lines 2-10): "Third, we included studies of all types of interventions targeted at health care professionals in the meta-analyses. Subgroup analyses showed that there was no significant difference between subgroups of interventions (professional, organizational, and professional plus organizational). But more detailed analyses, e.g. on duration or intensity of the intervention, were impossible due to the limited number of studies. The length of patient follow-up varied across studies. This issue might increase the clinical heterogeneity of outcomes measured."
An outcome might be not significantly improved in individual studies, but when pooling data of all studies into the meta-analysis, the power to detect (a small) improvement might increase. This may explain the finding of improved prescribing of statins. But although we found a significant effect on prescribing of statins, due to not finding any other effects, the overall conclusion does take this into account.
Reviewer's comment 14: Discussion: Discussion should be added regarding combining heterogeneous studies in a meta analysis regardless of I2 values Authors' response 14:
We agree with the reviewer that this is a limitation of our study. It is heterogeneity regarding the intervention, but also study methods, such as length of follow-up. We acknowledged this issue in the discussion section as follows (page 13, lines 51-57 and page 14, lines 2-10): "Third, we included studies of all types of interventions targeted at health care professionals in the meta-analyses… But more detailed analyses, e.g. on duration or intensity of the intervention, were impossible due to the limited number of studies. The length of patient follow-up varied across studies. This issue might increase the clinical heterogeneity of outcomes measured."
Reviewer's comment 15: Discussion: The lack of low/middle income countries could be a result of your search strategy and exclusion of non-English language papers rather than a lack of studies, this should be acknowledged Authors' response 15:
We have included this point now as a limitation in the discussion section as highlighted above as follows (page 14, lines 20-26): "Finally, our review included only studies published in English and we did not search for gray literature. So we may have missed relevant unpublished or locally published studies."
Reviewer's comment 16: Discussion: I disagree with the statement on page 11, lines 23-28: "Most likely the high baseline performance, especially of antiplatelet agents, limited the scope for further improvement". Prescribing behaviour is complex and involves a multitude of different barriers. Therefore you can't conclude why the interventions did not work without a full process evaluation. These other barriers, e.g. patient factors/ organisational constraints, need to be addressed. Furthermore, baseline prescribing should be presented in the results.
Authors' response 16: We have changed the manuscript as follows: (page 11, lines 31-37): "The high baseline performance, especially of antiplatelet agents, might limit the scope for further improvement." We intended to report baseline prescribing in the results, but the data were not available for all included studies, e.g., some studies did not report these data at all and others only provided aggregated data at baseline. Furthermore, we provide already a lot of results in the tables/appendices, therefore adding baseline prescribing (for some studies) increases the complexity of the presented data.
